Cefovecin Sodium is the sodium salt of Cefovecin, a broad-spectrum, third-generation cephalosporin with antibacterial properties. It is used for in vitro studies of the bacteria causing skin infections and urinary tract infections in veterinary research applications. It can also be used for comparative studies with other antibiotics to investigate interactions, in lab setting to review its activity against emerging or resistant strains, and in pharmacokinetic studies with different animal species and interaction studies with other compounds due to its high protein binding capacity.
Cefovecin Sodium is very soluble in water.
| Mechanism of Action |
Cephalosporins interfere with PBP (penicillin binding protein) activity involved in the final phase of peptidoglycan synthesis. PBP’s are enzymes which catalyze a pentaglycine crosslink between alanine and lysine residues providing additional strength to the cell wall. Without a pentaglycine crosslink, the integrity of the cell wall is severely compromised and ultimately leads to cell lysis and death. Resistance to cephalosporins is commonly due to cells containing plasmid encoded β-lactamases or from other methods. Resistance may be chromosomal or plasmid-encoded and could be transferred if associated with transposons or plasmids. Cross-resistance is also possible with other cephalosporins and other beta-lactams. |
| Spectrum | Broad-spectrum, including Gram-positive and Gram-negative bacteria. Representative organisms include Staphylococcus pseudintermedius and Pasteurella multocida that cause skin infections in canines and felines. Cefovecin differs from other cephalosporins as it is highly protein bound and has a long duration of activity. It has unique pharmacokinetics and it has bactericidal activity. Cefovecin shows in vitro activity against E. coli that is associated with canine and feline urinary tract infections. |
| Mechanism of Action |
Cefovecin is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative isolates. Medical microbiologists use AST results to recommend antibiotic treatment options. Representative MIC values include: For a representative list of Cefovecin MIC values, click here. In vitro efficacy of Cefovecin was evaluated against anaerobic bacteria from subgingival plaque of canine and feline samples with periodontal disease (PD). Select bacteria were identified to species level with 16S rRNA gene sequencing. Isolates were Porphyromonas (gulae, crevioricanis, macacae, canginivalis) Fusobacterium (nucleatum, russi) and Solobacterium moorei. All were highly susceptible (MIC90 of <=0.125 ug/ml. Poor compliance with veterinary oral antimicrobial treatment has created a trend in antimicrobial resistance including in some PD pathogens (Khazandi et al, 2014). Cefovecin disk-diffusion test was used to detect presence of mecA gene in Staphylococcus pseudintermedius. The test was useful to predict mecA gene carriage as well as the in vivo efficacy of the compound in canines with superficial pyoderma (Iyori et al, 2013). |
| Molecular Formula | C17H18N5NaO6S2 |
| References |
Iyori K, Toyoda Y, Ide K, Iwasaki T, Nishifuji K (2013) Usefulness of Cefovecin disk-diffusion test for predicting mecA gene-containing strains of Staphylococcus pseudintermedius and clinical efficacy of Cefovecin in dogs with superficial pyoderma. Vet. Dermatol. 24(1):162-167.e35-6 PMID 23331693 Khazandi M et al (2014) In vitro efficacy of Cefovecin against anaerobic bacteria isolated from subgingival plaque of dogs and cats with periodontal disease. Anaerobe 28:104-108 Passmore CA, Sherington J, Stegemann MR (2007) Efficacy and safety of Cefovecin (Convenia) for the treatment of urinary tract infections in dogs. J. Small Anim. Pract. 48(3):139-144 PMID 17355604 Thuesen LR, Bertelsen MF, Brimer L, Skaanild MT (2009) Selected pharmacokinetic parameters for Cefovecin in hens and green iguanas. J. Vet. Pharmacol. Ther. 32(6):613-617 PMID 20444017 |
